Portolan Capital Management LLC Cuts Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Portolan Capital Management LLC trimmed its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 60.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 131,123 shares of the company’s stock after selling 196,641 shares during the period. Portolan Capital Management LLC owned 0.27% of Amphastar Pharmaceuticals worth $4,869,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Pacer Advisors Inc. grew its stake in shares of Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after buying an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp raised its stake in shares of Amphastar Pharmaceuticals by 81.4% during the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after purchasing an additional 439,281 shares during the period. Geode Capital Management LLC lifted its position in shares of Amphastar Pharmaceuticals by 1.5% during the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock worth $44,674,000 after purchasing an additional 14,015 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Amphastar Pharmaceuticals by 7.4% in the fourth quarter. Renaissance Technologies LLC now owns 525,500 shares of the company’s stock valued at $19,512,000 after purchasing an additional 36,100 shares during the period. Finally, Bessemer Group Inc. grew its holdings in Amphastar Pharmaceuticals by 2.4% during the 4th quarter. Bessemer Group Inc. now owns 488,630 shares of the company’s stock valued at $18,144,000 after purchasing an additional 11,609 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 27.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on AMPH shares. Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday.

Amphastar Pharmaceuticals Stock Performance

Shares of Amphastar Pharmaceuticals stock opened at $24.16 on Monday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm has a market cap of $1.15 billion, a PE ratio of 8.05, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 1 year low of $22.74 and a 1 year high of $53.96. The firm’s 50-day simple moving average is $28.68 and its 200-day simple moving average is $38.07.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.